HOKLAS SC-35	
Issue No. 5	

Issue Date: 29 May 2025

Implementation Date: 29 May 2025

Page 1 of 10

# **HOKLAS Supplementary Criteria No. 35**

# 'Medical Testing' Test Category – Cytogenomics

## 0 Introduction

This document is an application document for the requirements of HKAS 002, as well as either (1) HOKLAS 015 (5<sup>th</sup> edition), or (2) ISO 15189:2022 and HKAS PD002, for accreditation of laboratories for cytogenomic examinations within the test category of 'Medical Testing'. This document provides further elaboration on particular requirements only, it does not include all the accreditation requirements. Therefore, the document has to be read in conjunction with HKAS 002, either (1) HOKLAS 015 (5<sup>th</sup> edition), or (2) ISO 15189:2022 and HKAS PD002, as well as HOKLAS SC-33.

## 1 Scope

HKAS provides accreditation under HOKLAS for cytogenomics in the following areas:

- 1.1 Constitutional Cytogenetics (prenatal and postnatal)
- 1.2 Cancer Cytogenetics (excluding solid tumours)
- 1.3 Fluorescence in situ hybridisation (FISH)
- 1.4 Chromosomal Microarray Analysis (CMA)
  - 1.4.1 array comparative genomic hybridisation (array CGH)
  - 1.4.2 single nucleotide polymorphism array (SNP array)

## 2 Normative references

(No additional explanation)

## **3** Terms and definitions

(No additional explanation)

HOKLAS SC-35	
Issue No. 5	
Issue Date: 29 May 2025	
Implementation Date: 29 May 2025	
Page 2 of 10	

#### **4** General requirements

(No additional explanation)

## 5 Structural and governance requirements

(No additional explanation)

#### **6** Resource requirements

#### 6.2 Personnel

#### 6.2.2 Competence requirements

- (a) Medical personnel
  - (i) A qualified pathologist providing consultation and clinical interpretation for test results in any test areas of cytogenomics shall have obtained the Fellowship of the Hong Kong College of Pathologists (HKCPath) or equivalent as advised by the College in an appropriate specialty, plus either:
    - the Fellowship in Genetic and Genomic Pathology of the HKCPath;

or

• qualification in relevant subjects in cytogenomics from a university and/or professional body and 2 years' post-fellowship full-time equivalent laboratory experience in a clinical laboratory providing cytogenomic test services;

or

- at least 5 years of laboratory experience in a laboratory providing the cytogenomic test services before 1 September 2008 (the launching date of HOKLAS for the accreditation of tests and examinations in Medical Genetics).
- (ii) A qualified pathologist nominated by a laboratory to be its signatory for any test areas in cytogenomics, who has not obtained the Fellowship in Genetic and Genomic Pathology of the HKCPath, shall seek endorsement from the HKCPath that his/her training and experience meet the

HOKLAS SC-35
Issue No. 5
Issue Date: 29 May 2025
Implementation Date: 29 May 2025
Page 3 of 10

requirements of a signatory for such tests. It will be the responsibility of the pathologist to seek endorsement from the HKCPath and provide HKAS Executive with the written confirmation from the HKCPath.

- (iii) The relevant test scope in cytogenomics where consultation and clinical interpretation are provided shall align with the specialty of the pathologist. In case of doubt, HKAS shall seek endorsement from the HKCPath.
- (iv) A medically qualified person nominated by a laboratory to be its signatory to provide consultation and clinical interpretation for test results in cytogenomics shall have obtained Fellowship in an appropriate specialty (e.g. Obstetrics and Gynaecology, Paediatrics), plus either:
  - qualification in the relevant subjects in cytogenomics from a university and/or professional body and 2 years' post-fellowship full-time equivalent laboratory experience in a clinical cytogenomic laboratory;

or

- at least 5 years of laboratory experience in a laboratory providing the cytogenomic test services before 1 September 2008.
- (b) Technical personnel
  - (i) A biomedical scientist reporting test results in cytogenomics without clinical interpretation shall be MLT Board Part I registered (or exempted from such registration) and have obtained either:
    - a BSc degree or above in a relevant subject plus 5 years of post-Part I registration supervisory experience in cytogenomics;

or

• a recognised overseas qualification in cytogenomics from a university and/or professional body.

## 6.4 Equipment

#### 6.4.1 General

(a) Procedures to assure and verify the proper functioning of equipment shall meet acceptable standards, e.g. HOKLAS SC-38 "'Medical Testing' Test

HOKLAS SC-35
Issue No. 5
Issue Date: 29 May 2025
Implementation Date: 29 May 2025
Page 4 of 10

Category - Performance Verification of Automated Analysers".

(b) Tissue culture incubators shall have a system to monitor the temperature continuously, and an alarm system to alert laboratory staff of abnormal culture conditions.

## 7 Process requirements

#### 7.2 **Pre-examination processes**

#### 7.2.3 Requests for providing laboratory examinations

- (a) Both the request form and specimen submitted for cytogenomic studies shall each contain at least two independent identifiers for unique identification of the patient. The identifying information on the request form shall be identical to that on the specimen tube label. There shall be a system to identify the person collecting the specimen for the test.
- (b) The laboratory shall only accept test requests for CMA, where relevant, with appropriate genetic counselling and consent documented.

#### 7.3 Examination processes

## 7.3.1 General

- (a) Each prenatal specimen for cytogenetic studies shall be divided, cultured in two separate incubators and maintained with independent cell cultures, media and reagents. Duplicate or independently established cultures should be included if adequate specimen is available.
- (b) For cytogenetic studies, adequate number of banded metaphases should be examined. In general, a minimum of 5 cells (10 for cancer cytogenetics) should be analysed, and at least two cells shall be checked by a qualified personnel as defined in section 6.2.2. When there is evidence of mosaicism or clonal evolution, further cells should be examined.
- (c) For FISH studies, an effort should be made to examine a few metaphases with reverse DAPI chromosome staining to confirm that the correct probes have been used and to identify any unusual signal pattern. If metaphase is absent or inherent control signal is not available, the test should be repeated in parallel with another sample known to have the target of the probes.
  - (i) There shall be a clear and consistent definition of fluorescence signals

HOKLAS SC-35
Issue No. 5
Issue Date: 29 May 2025
Implementation Date: 29 May 2025
Page 5 of 10

and also criteria for false positive and false negative signals.

- (ii) Adequate number of interphase nuclei or metaphases should be examined. In general, a minimum of 5 metaphases and/or 100 interphase nuclei should be studied and scored. FISH signals shall be scored independently by 2 people.
- (d) CMA of cancers often requires the testing of small genomic aberrations in a mixed cell population. The laboratory shall understand the limitations of the test and in particular, the type of specimens (such as blood, fresh and formalin-fixed paraffin embedded tissues), tumour heterogeneity, contamination by normal DNA, selection of CMA platforms, coverage of the region of interest and the need for reference DNA (matched or pooled).
- (e) For CMA, the following experiment design and validation shall be considered:
  - (i) All processes and parameters of CMA, including new array designs, shall be validated using DNA from a range of known abnormal samples, including numerical and structural variation, microdeletion and microduplication. Correct identification of a defined and reasonable number of abnormal specimens is suggested. Where a limited number is used for validation, there shall be documentation of justification and on-going data accumulation to complete the validation process. For validation of an updated version of a microarray platform, correct identification of at least five known abnormal samples is suggested.
  - (ii) If an enhanced (or a new) version of platform is used, it shall be validated with abnormal samples that reflect the additional capacity of the platform. A single algorithm or software programme shall be used throughout.
  - (iii) If an in-house assay is developed, the laboratory shall validate each clone or region using alternative method and reference DNA.
  - (iv) For an individual application, a single algorithm and set of parameters shall be used for all data analysis. The laboratory shall re-analyse all data used for initial validation if an alternative algorithm is used.
  - (v) Software packages should produce diagrammatic and numerical output for analysis. Software parameters shall be defined and documented to ensure detection of imbalance at, or greater than, the level specified by the laboratory. A minimum genome-wide resolution at 400 kb is recommended.

HOKLAS SC-35	
Issue No. 5	
Issue Date: 29 May 2025	
Implementation Date: 29 May 2025	
Page 6 of 10	

#### 7.3.4 Evaluation of measurement uncertainty (MU)

For tests that give quantitative results, the laboratory shall determine the uncertainty of measurement and document the uncertainty components. An example is FISH study with quantitative results.

#### **7.3.6** Documentation of examination procedures

For CMA, the laboratory shall have written procedures for DNA extraction, quality, yield and quantitation, proper fragmentation and fluorescent labelling. The laboratory shall also have a standard protocol for the confirmation of abnormal or ambiguous results CMA results by alternative techniques, such as FISH, PCR, as far as is reasonably practicable.

## **7.3.7** Ensuring the validity of examination results

#### 7.3.7.3 External quality assessment (EQA)

- (a) All staff taking part in the testing activities shall participate in appropriate external quality assessment or interlaboratory comparison programme.
- (a) In the absence of EQAP, both normal and abnormal samples shall be included in the interlaboratory comparison programme.

#### 7.4 Post-examination processes

## 7.4.1 Reporting of results

#### 7.4.1.2 Result review and release

- (a) The description of test results shall follow the latest version of the International System for Human Cytogenomic Nomenclature (ISCN). For cancer cytogenetics and FISH studies in haematology, the tests shall be reported by a qualified haematologist with appropriate training and laboratory experience.
- (b) For FISH studies in Anatomical Pathology, the tests shall be reported by a qualified anatomical pathologist with appropriate training and laboratory experience.
- (c) For constitutional cytogenetics, the tests shall be reported by a medically qualified person with appropriate training and laboratory experience as required in section 6.2.2. For those tests with normal

HOKLAS SC-35
Issue No. 5
Issue Date: 29 May 2025
Implementation Date: 29 May 2025
Page 7 of 10

results, numerical autosomal or sex chromosome abnormalities of well-recognised syndromes and common chromosomal polymorphism (an indicative list is given in Appendix 1), they may be reported by a biomedical scientist. Clinical interpretation shall not be provided in such reports. Communication of the significance of the finding to referring doctor is advised.

## 7.4.1.6 Requirements for reports

- (a) A cytogenetics report shall contain:
  - (i) biological box of the patient;
  - (ii) description of specimen / tissue studied;
  - (iii) number of cells (metaphases) analysed, counted and karyotyped;
  - (iv) banding method(s) used; and
  - (v) diagnosis and classification according to the WHO classification (for haematology malignancies)
- (b) For FISH studies, information on the limitations of the test applied, on the source of the probe and on the implications of the result shall be included in the report.
- (c) For CMA, the following information shall be provided in the report for the diagnosis of constitutional disorders in addition to the information described in either clause 5.8.3 of HOKLAS 015 (5th edition), or clauses 7.4.1.6 and 7.4.1.7 of ISO 15189:2022:
  - (i) Date of specimen reception at the laboratory;
  - (ii) Pedigree information (optional);
  - (iii) Clinical disorder or indications for testing;
  - (iv) Gene(s) and/or specific region or mutation(s) of interest analysed, if applicable (standard nomenclature of Human Genome Organisation Gene Nomenclature Committee (HGNC) shall be used);
  - (v) Brief description of the technical information, such as commercial source, the number and type of clones and loci tested, the version number of array chip and software programme used for the analysis;
  - (vi) Database accession number and version number for the reference sequence or genome, if applicable;
  - (vii) Test performance specifications and limitations (e.g. mosaicism, balanced rearrangements, etc.);

HOKLAS SC-35
Issue No. 5
Issue Date: 29 May 2025
Implementation Date: 29 May 2025
Page 8 of 10

- (viii) Test sensitivity with quoted source reference, if available (e.g. the proportion of affected individuals likely to be detected);
- (ix) A remark to notify the requesting clinician that post-test genetic counselling service has to be provided to the patient if necessary;
- (x) Comments or recommendations on family study;
- (xi) A summary statement, where applicable (e.g. current ISCN nomenclature for copy number variant identified).

#### 7.4.1.7 Additional information for reports

- (a) The laboratory shall have established criteria to identify copy number variation (CNV) and the corresponding reportable range in CMA with reference to international guidelines such as the American College of Medical Genetics and Genomics (ACMG).
- (b) The laboratory shall keep information of available genetic counselling service.
- (c) Where appropriate, the test report shall include a recommendation that the patient should obtain genetic counselling from a qualified healthcare professional.

## 7.4.2 Post-examination handling of samples

- (a) A minimum of two karyotypes/images shall be prepared and archived.
- (b) Storage of the primary specimens and other laboratory samples shall be in accordance with the requirements given in Table 1. Laboratories should retain records and/or materials for a longer period of time than specified when such is appropriate for patient care, education, quality improvement needs or legal requirements, etc.

#### 8 Management system requirements

(No additional explanation)

HOKLAS SC-35
Issue No. 5
Issue Date: 29 May 2025
Implementation Date: 29 May 2025
Page 9 of 10

# Table 1 - Retention of Laboratory Records and Materials

		Record/material	Requirement
G	eneral	Records of employee signatures, initials, and identification codes	10 years
		Referring doctor's request	4 years after dispatch of final report. Indefinite for request form which contains clinical information not readily accessible in the patient's notes but used in the interpretation of test result. Where the request form is used to record working notes or as a worksheet, it should be retained as part of the laboratory record.
•	Cytogenomics	Copies of reports	Indefinite
•	Fluorescence in situ hybridisation (FISH)	Patient information/karyotypes	Indefinite
•	Chromosomal microarray analysis (CMA)	Slides	4 years after final report if photographic record kept; 5 years otherwise, unless degeneration evident
		Original specimen and container/wet specimen/tissue	1 month after reporting
		DNA and RNA extract, and amplified DNA product	1 month after reporting, and indefinite where appropriate
		Fixed chromosome preparation (blood, bone marrow)	Abnormal: indefinite Normal: 6 months
		Tissue culture/cell culture	Cryopreserved, and indefinite when appropriate
		Diagnostic images (digitised or negatives)	Indefinite
		CMA data	Indefinite

N.B.: Indefinite means without limit of time, but not less than 30 years.

HOKLAS SC-35
Issue No. 5
Issue Date: 29 May 2025
Implementation Date: 29 May 2025
Page 10 of 10

#### Appendix 1

An indicative list of the numerical autosomal or sex chromosome abnormalities of well-recognised syndromes and common chromosomal polymorphism.

- A. Non-mosaic numerical abnormalities:
  - 1. 47,XX,+21 or 47,XY,+21
  - 2. 45,X
  - 3. 47,XX,+13 or 47,XY,+13
  - 4. 47,XX,+18 or 47,XY,+18
  - 5. 47,XXY
  - 6. 47,XXX
  - 7. 47,XYY
  - 8. 69,XXX or 69,XXY or 69,XYY
- B. Common chromosomal polymorphism:
  - 1. 46,XX,inv(9)(p11q13) or 46,XY,inv(9)(p11q13)
  - 2. 46,XX,inv(9)(p11q12) or 46,XY,inv(9)(p11q12)